Molecular Docking and Dynamics-Based Repurposing of Thalidomide and Lenalidomide for GSK-3β Inhibition in AD
LS9 is a promising GSK-3β inhibitor with potential for AD therapy. Its robust binding, safety profile, and MD stability warrant further investigations.
Authors
- Pallavi Kumari Singh (ORCID: https://orcid.org/0000-0003-0544-4447)
- Siddharth Goswami
- Shiva Prasad Kollur (ORCID: https://orcid.org/0000-0003-3914-3933)
- Shivangi Singh (ORCID: https://orcid.org/0009-0006-3984-8107)
- Arunima Nayak
Institutions
- All India Institute of Medical Sciences, Nagpur (IN)
- Graphic Era University (IN)
- Amrita Vishwa Vidyapeetham (IN)
Publication Details
- Journal
- CNS & Neurological Disorders - Drug Targets
- Published
- 2026-03-13
- DOI
- https://doi.org/10.2174/0118715273411602251130120518
- Primary Topic
- Cholinesterase and Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00